Leading Nousom’s pipeline is off-the-shelf vaccine NOUS-209, which targets 209 shared neoantigens and is being tested alongside MSD’s checkpoint inhibitor Keytruda (pembrolizumab) in a phase 2 ...

In GALAXIES, there was a “clinically meaningful” reduction at every dose of the combination tested compared to monotherapy with Jemperli or MSD’s PD-1 inhibitor Keytruda (pembrolizumab ...

Merck's injected version of its blockbuster cancer drug Keytruda could face a potential patent challenge from biotech ...

Drugmaker Merck said on Tuesday it expects its top selling cancer therapy Keytruda to be selected in 2026 for government price setting, which would become effective on January 1, 2028.

Shares in pharmaceuticals giant Merck (MRK) weakened today on fears that a patent battle could jeopardize its plans to sell a ...

Merck (MRK) has been adjusting Keytruda to make it easier to use and to protect the company for after the U.S. patent protection runs out in ...

Both Merck & Co. and Halozyme are holding their ground in a freshly unveiled patent dispute surrounding the New Jersey pharma’s under-the-skin version of its blockbuster cancer drug Keytruda.

DelveInsight's "BAVENCIO Market Size, Forecast, and Market Insight Report" highlights the details around BAVENCIO, a human ...

The combination of Padcev and Keytruda showed promising clinical activity in UTUC patients, with a 25% ORR in primary lesions and 35% in target lesions. The study included 22 patients with intact ...

The safety profile of the combination therapy remains consistent, with no new adverse effects observed. Padcev plus Keytruda was found to maintain benefit over chemotherapy in untreated locally ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Adding ...